Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Spruce Biosciences Inc (Spruce Biosciences) is a biopharmaceutical company that develops and commercializes drugs, novel therapies for the rare endocrine disorders with significant unmet medical need. It's product pipeline include Tildacerfont, a CRF1 receptor antagonist to treat adult and pediatric classic congenital adrenal hyperplasia and polycystic ovary syndrome. The company focuses on reducing the hyperresponsiveness of adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol and improve disease control and glucocorticoid steroid burden. The company offers services such as medical services, healthcare services, clinical trials among others. Spruce Biosciences is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
611 Gateway Boulevard, Suite 740, South San Francisco, California, 94080
Website
www.sprucebiosciences.com
Telephone
1 415 6554168
No of Employees
22
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SPRB (NASD)
Revenue (2022)
$10.1M
EPS
XYZ
Net Income (2022)
XYZ
-3.8%
(2022 vs 2021)
Market Cap*
$27.7M
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Spruce Biosciences Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Clinical Trials |
| Tildacerfont: | Medical Services |
| Adult and Pediatric Classic Congenital Adrenal Hyperplasia | Healthcare Services |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In January, the company entered into a licensing agreement with Kaken Pharmaceutical Co. Ltd for the development and commercialization of Spruce’s product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia in Japan. |
| 2014 | Incorporation/Establishment | The company was incorporated |
Competitor Comparison
| Key Parameters | Spruce Biosciences Inc | Crinetics Pharmaceuticals Inc | Tempest Therapeutics Inc | Lipocine Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | San Diego | Brisbane | Salt Lake City |
| State/Province | California | California | California | Utah |
| No. of Employees | 22 | 290 | 17 | 17 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Grey | Director; Chairman | Executive Board | 2017 | 70 |
| Javier Szwarcberg, M.D., MPH | Director; Chief Executive Officer | Executive Board | 2022 | 53 |
| Samir Gharib, MBA | President; Chief Financial Officer | Senior Management | 2022 | 40 |
| Ralph William Charlton III, M.D., M.A.S | Chief Medical Officer | Senior Management | 2022 | 53 |
| Dasharatha Reddy, Ph.D. | Vice President - Pharmaceutical Development and Manufacturing | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer